Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Fluzoparib
2. 4-((4-fluoro-3-(2-(trifluoromethyl)-6,8-dihydro-5h-(1,2,4)triazolo(1,5-a)pyrazine-7-carbonyl)phenyl)methyl)-2h-phthalazin-1-one
3. Shr3162
1. Fluzoparib
2. 1358715-18-0
3. Fuzuopali
4. Shr-3162
5. Shr3162
6. Twf0ml1ck8
7. 4-[[4-fluoro-3-[2-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[1,5-a]pyrazine-7-carbonyl]phenyl]methyl]-2h-phthalazin-1-one
8. Hs10160
9. Hs-10160
10. 1(2h)-phthalazinone, 4-((3-((5,6-dihydro-2-(trifluoromethyl)(1,2,4)triazolo(1,5-a)pyrazin-7(8h)-yl)carbonyl)-4-fluorophenyl)methyl)-
11. 4-((3-((5,6-dihydro-2-(trifluoromethyl)(1,2,4)triazolo(1,5-a)pyrazin-7(8h)-yl)carbonyl)-4-fluorophenyl)methyl)-1(2h)-phthalazinone
12. Airuiyi
13. 4-((4-fluoro-3-(2-(trifluoromethyl)-6,8-dihydro-5h-(1,2,4)triazolo(1,5-a)pyrazine-7-carbonyl)phenyl)methyl)-2h-phthalazin-1-one
14. Refchem:141090
15. 4-((4-fluoro-3-(2-(trifluoromethyl)-5h,6h,7h,8h-(1,2,4)triazolo(1,5-a)pyrazine-7-carbonyl)phenyl)methyl)-1,2-dihydrophthalazin-1-one
16. Unii-twf0ml1ck8
17. Fluzoparib (shr-3162)
18. 4-(4-fluoro-3-(2-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine-7-carbonyl)benzyl)phthalazin-1(2h)-one
19. Fluzoparib?
20. 25i
21. Fuzuloparib [inn]
22. Fluzoparib [who-dd]
23. Orb1298619
24. Chembl3930624
25. Schembl10025553
26. Schembl29361923
27. Schembl30641389
28. Gtpl13763
29. C22h16f4n6o2
30. Dtxsid801374052
31. Glxc-23874
32. Hms5086g20
33. Ex-a8180
34. Shr3162; Fuzuopali; Fuzuloparibum
35. S9712
36. Ms-28738
37. Hy-114778
38. Cs-0064303
39. G17612
| Molecular Weight | 472.4 g/mol |
|---|---|
| Molecular Formula | C22H16F4N6O2 |
| XLogP3 | 2.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 3 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 92.5 |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 839 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of prostate cancer
Poly(ADP-ribose) Polymerase Inhibitors
Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES.
ABOUT THIS PAGE
90
PharmaCompass offers a list of Fuzuloparib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Fuzuloparib manufacturer or Fuzuloparib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fuzuloparib manufacturer or Fuzuloparib supplier.
A Fuzuloparib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fuzuloparib, including repackagers and relabelers. The FDA regulates Fuzuloparib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fuzuloparib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Fuzuloparib supplier is an individual or a company that provides Fuzuloparib active pharmaceutical ingredient (API) or Fuzuloparib finished formulations upon request. The Fuzuloparib suppliers may include Fuzuloparib API manufacturers, exporters, distributors and traders.
Fuzuloparib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fuzuloparib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Fuzuloparib GMP manufacturer or Fuzuloparib GMP API supplier for your needs.
A Fuzuloparib CoA (Certificate of Analysis) is a formal document that attests to Fuzuloparib's compliance with Fuzuloparib specifications and serves as a tool for batch-level quality control.
Fuzuloparib CoA mostly includes findings from lab analyses of a specific batch. For each Fuzuloparib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fuzuloparib may be tested according to a variety of international standards, such as European Pharmacopoeia (Fuzuloparib EP), Fuzuloparib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fuzuloparib USP).
